Inject once a week! Noel and Nord's long-acting insulin icodec is declared clinical in China.

On September 21st, Novo Nordiak's clinical application for icodec insulin injection in China was accepted by CDE, a basic insulin similar to a weekly injection.
On June 15 this year, Noor and Nord announced the results of a Phase II clinical trial of the basic insulin-liker icodec insulin once a week, at the 80th annual meeting of the American Diabetes Association (ADA), showing that their blood sugar control and safety characteristics for treating adult type 2 diabetics are similar to those of insulin glyceride U100, which is injected daily.
The Phase II clinical study, which lasted 26 weeks, included 247 adult type 2 diabetes patients who had not previously used insulin, who had not previously used metformin, who had not used metformin or who did not use DEP-4i to control poorly, with the aim of comparing the efficacy and safety differences between icodec insulin injected once a week and insulin glyceride U100 injected daily.
end point is the HbA1c change from baseline to 26 weeks.
end points include changes in peri-abdominal blood sugar from baseline to 26 weeks and the number of hypoglycemia events.
phase 2 was conducted in the United States, Canada, the Czech Republic, Greece, Poland, Slovakia and Slovenia.
results showed that participants who received weekly injections of icodec insulin from baseline to 26 weeks had similar changes in blood sugar control (HbA1c) to participants who received daily insulin glycemic U100 treatment (-1.33% vs -1.15%, p-0.08, respectively) to reach the primary endpoint.
secondary endpoints included changes in peri-abdominal blood sugar from baseline to 26 weeks, similar changes in the icodec insulin group and insulin glycemic U100 (-58mg/dL and -54mg/dL, respectively); p - 0.01).
safety, the rates of hypoglycemia were similar in the two treatment groups, and no new safety issues associated with icodec insulin were found.
icodec insulin is a long-acting underlying insulin similar in study with a half-life of 196 hours.
icodec insulin binds tightly but reversiblely to albumin when injected into the body.
results can reduce blood sugar continuously, slowly and steadily over a period of one week.
based on its concentrated formula, the amount of icodec insulin injected once a week is comparable to the amount of insulin Glycelin U100 injected daily.
Dr. Julio Rosenstock, lead researcher on the study and professor of clinical medicine at the University of Texas Southwestern Medical Center, said, "I'm really excited about the potential of this innovative treatment that reduces the number of basic insulin injections for people with type 2 diabetes because they need injections every day."
" about icodec insulin icodec insulin is a long-acting underlying insulin similar in study with a half-life of 196 hours.
2 is injected into the body, icodec insulin binds tightly but reversiblely to albumin.
results can reduce blood sugar continuously, slowly and steadily over a period of one week.
based on its concentrated formula, the amount of icodec insulin injected once a week is comparable to the amount of insulin Glycelin U100 injected daily.
Network Source: Web Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.